Posaconazole for the management of mucosal candidiasis

Future Microbiology

Volumn 2, Issue 3, 2007, Pages 245-256

  Vazquez, Jose A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Esophageal candidiasis; HIV infection; Oropharyngeal candidiasis; Posaconazole

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTACID AGENT; ANTIFUNGAL AGENT; ASTEMIZOLE; CASPOFUNGIN; CIMETIDINE; CISAPRIDE; CLOTRIMAZOLE; CYCLOSPORIN; DIDANOSINE; DIGOXIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LANSOPRAZOLE; MICAFUNGIN; MIDAZOLAM; NYSTATIN; OMEPRAZOLE; PHENYTOIN; PLACEBO; POSACONAZOLE; PROTEINASE INHIBITOR; RANITIDINE; RIFAMPICIN; SUCRALFATE; TRIAZOLAM; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CANDIDA; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; FLATULENCE; FLUSHING; FOOD DRUG INTERACTION; FUNGAL STRAIN; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OROPHARYNX CANDIDIASIS; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; RECURRENT INFECTION; SIDE EFFECT; TASTE DISORDER; VISUAL DISORDER;

ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANDIDIASIS, ORAL; HIV INFECTIONS; HUMANS; MOLECULAR STRUCTURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIAZOLES;

CANDIDA; GENTIANA;

EID: 34547573733     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.2.3.245     Document Type: Article

References (73)

1. Odds FC: Candida and Candidosis. A review and bibliography. London. Baillière Tindall (1998).
2. Vazquez JA, Sobel JD: Candidiasis. In: Clinical Mycology (1st Edition). Dismukes WE, Pappas PG, Sobel JD (Eds). Oxford University Press, UK 143-187 (2003).
3. Johnston RD, Chick EW. Johnston NS et al.: Asymptomatic quantitative increase of Candida albicans in the oral cavity: predisposing conditions. South. Med. J. 60. 1244-1247 (1967).
4. Hippocrates CA, Adams F: In: Epidemics (3rd Edition). Williams and Wilkins, Baltimore. USA (1939).
5. Coker RJ, Fisher M. Tomlinson DR: Management of mycoses associated with HIV disease. Int. J. STD AIDS 6, 408-412 (1994).
6. Silverman S Jr. Gallo JW, McKnight ML et al.: Clinical characteristics and management responses in 85 HIV-Infected patients with oral candidiasis. Oral Surg. Oral. Med. Oral Pathol. Oral Radiol. Endod. 82, 402-407 (1996).
7. Dupont B, Denning DW, Marriot D et al.: Mycosis in AIDS. J. Med. Vet. Mycology 32(Suppl.), 65-77 (1994).
8. Moore RD, Chaisson RE: Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann. Intern. Med. 124, 633-642 (1996).
9. Scott BB, Jenkins D: Gastro-oesophageal candidiasis. Gut 23, 137-139 (1982).
10. Pappas PG, Rex JH, Sobel JD et al.: Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38, 161-189 (2004).
11. Imam N. Carpenter CC, Mayer KH et al.: Hierarchical pattern of mucosal Candida infections iIn HIV-seropositive women. Am. J. Med. 89(2). 142-146 (1990).
12. Barchiesi F. Morbiducci V. Ancarani F et al.: Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur. J. Epidemiol. 9, 455-456 (1993).
13. Van't Wout JW: Fluconazole treatment of candidal infections caused by non-albicans Candida species. Eur J. Clin. Microbiol. Infect. Dis. 15, 238-242 (1996).
14. Reef SE, Meyer KH: Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities. Clin. Infect. Dis. 21 (Suppl. 1), S99-S102 (1995).
15. Darouiche RO: Oropharyngeal. and esophageal candidiasis in immunocompromised patients: treatment issues. Clin. Infect. Dis. 26, 259-274 (1998).
16. Vazquez JA: Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. Pharmacotheraphy 19, 76-87 (1999).
17. Vazquez JA, Sobel JD: Epidemiologic overview of resistance to oral antifungal agents in the Immunocompromised host. Excerpta Med. 1-11 (1997) (Abstract).
18. Maenza JR, Keruly JC, Moore RD et al.: Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J. Infect. Dis. 173, 219-225 (1996).
19. Kozinin PJ, Taschdjian CL, Dragutsky D et al.: Therapy of oral thrush: a comparative evaluation of gentian violet, mycostatin and amphotericin B. Monagr. Ther. 2, 16-24 (1957).
20. Quintiliani R, Owens NJ, Quercia RA et al.: Treatment and prevention of oropharyngeal candidiasis. Am. J. Med. 77(Suppl. 4D), 44-48 (1994).
21. Pons V, Greenspan D. Lozada-Nur F et al.: Cropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin. Infect. Dis. 24, 1204-1207 (1997).
22. Pons V. Greenspan D. Debruin M et al.: Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. J. Acquir. Immune Defic. Syndr. 6, 1311-1316 (1993).
23. Como JA, Dismukes WE: Oral azole drugs as systemic antifungal therapy. N. Eng. J. Med. 330, 263-272 (1994).
24. Hughes WT, Bartley DL, Patterson GG et al.: Ketoconazole and candidiasis: a controlled study. J. Infect. Dis. 147, 1060-1063 (1983).
25. DeWit S, Weerts D, Goossens H et al.: Comparison of fluconazole and ketonazole for oropharyngeal candidiasis in AIDS. Lancet 1, 746-748 (1989).
26. Como I, Dismukes WE: Azole antifungal drugs. In: Clinical Mycology (1st Edition ). Dismukes AVE, Pappas PG, Sobel JD (Eds). Oxford University Press, UK 64-87 (2003).
27. Piscitelli, SC, Flexner C, Minor JR et al.: Drug interactions in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 23, 685-693 (1996).
28. Honig PK, Wortham DC, Zamani K et al.: Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269, 1513-1518 (1993).
29. Meyer JM, Rodvold KA: Drug biotransformation by the cytochrome P-450 enzyme system. Infect. Med. 452-464 (1996).
30. Hay RJ: Overview of studies of fluconazole in oropharyngeal candidiasis. Rev. Infect. Dis. 12(Suppl. 3), S334-S337 (1990).
31. Meunier F, Aoun M, Gerard M: Therapy oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs ketoconazole. Rev. Infect. Dis. 12(Suppl. 3), S364-S368 (1990).
32. Murray PA, Koletar SL, Mallegol I et al.: Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clin. Ther. 19, 471-480 (1997).
33. Koletar SL, Russell JA, Fass RJ et al.: Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 34, 2267-2268 (1990).
34. Barone JA, Moskovitz BL Guarnieri J et al.: Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution compared with capsules in healthy volunteers. Antimicrob. Agents Chemother. 42(7), 1862-1865 (1998).
35. Hostetler JS, Hanson LH, Stevens DA: Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob. Agents Chemother. 36, 477-480 (1992).
36. Van de Velde VJS, Van Peer AP, Heykants JJP et al.: Effect of food on the pharmacokinetics of a new hydroxypropyl-β-cyclodextrin formulation of itraconazole. Pharmacotheraphy 16, 424-428 (1996).
37. Graybill JR, Vazquez J, Darouiche RO et al.: Itraconazole oral solution: a novel and effective treatment for oropharyngeal candidiasis in HIV/AIDS patients. Am. J. Med. 104, 33-39 (1998).
38. Kowalsky SF, Dixon DM. Fluconazole: a new antifungal agent. Clin. Pharm. 10, 179-194 (1991).
39. Tucker RM, Denning DW, Hanson LH et al.: Interactions of azoles with rifampin phenytoin, and carbamazepine: in vitro and clinical observations. Clin. Infect. Dis. 14, 165-174 (1992).
40. Voriconazole, package insert. Pfizer, Inc., NY, USA.
41. Ally R, Schurmann D, Kreisel W et al.: A randomized double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33, 1447-1454 (2001).
42. Groll AH, Walsh TG: Cell wall synthesis inhibitors: echinocandins and nikkomycins. In: Clinical Mycology (1st Edition). Dismukes, WE, Pappas PG, Sobel JD (Eds). Oxford University Press, UK 88-103 (2003).
43. McCarthy GM, Mackie ID. Koval J et al.: Factors associated with increased frequency of HIV-related oral candidiasis. J. Oral Pathol. Med. 20, 332-336 (1991).
44. Herbrecht R: Posaconazole: a potent artended spectrum triazole antifungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 58(6), 612-624 (2004).
45. Posaconazole, package insert. Schering Corporation, NJ, USA.
46. Munayyer HK, Mann PA, Chau AS et al.: Posaconazole is a potent inhibitor of sterol 14 α demethylation in yeasts and molds. Antimicrob. Agents Chemother. 48, 3690 (2004).
47. Li X, Brown, Chau AS et al.: Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J. Antimicrob Chemother. 53, 74-80 (2004).
48. Xiao L, Madison C, Chaui AS et al.: Three-dimensional models of wild-type and mutated forms of cytochrome P450 14 α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48, 568-574 (2004).
49. Chau AS, Mendrick CA, Sabatelli FJ et al.: Application of real-time quantitive PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother. 48, 2124-2131 (2004).
50. Helmark L, Sbipkova P, Greene J et al.: Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesis. J. Mass Spectrom. 37, 265-269 (2002).
51. Sabatelli FJ, Patel R, Mann PA et al.: In vitro activities of posaconazole. fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinicall important molds and yeasts. Approximately 18,000 strains of clinically significant yeasts and moulds. Antimicrob. Agents Chemother. 50, 2009 (2006).
52. Ostrosky-Zeichner L, Rex JH, Pappas PG et al.: Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United states. Antimicrob. Agents Chemother. 47, 3149-3154 (2003).
53. Courtney R, Sansone A, Radwanski E et al.: Relative oral bioavailability of three formulations of posaconazole in healthy volunteers: basis for clinical development of the suspension. Presented at: 13th European Congress of Clinical Microbiology and Infectious Diseases. Glasgow, Scotland, UK, 10-13 May 2003 (Abstract).
54. Courtney R, Pai S, Laughlin M et al.: Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 47, 2788-2795 (2003).
55. Courtney R, Sansone A. Calzetta A et al.: The effect of a nutritional supplement (Boost Plus) on the oral bioavailability of posaconazole. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotheraphy. Chicago. IL, USA, 14-17 September 2003 (Abstract).
56. Courtney R, Wexler D. Radwanski E et al.: Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57, 218-222 (2004).
57. Ezzet F. Wexler D, Courtney R et al.: The oral bioavailability of posaconazole in fasted healthy subjects: basis for clinical dosage recommendations. Clin. Pharmacokinet. (2007) (In Press).
58. Krieter P. Flannery B, Musick T et al.: Pharmacokinetics and excretion of 14C posaconazole following oral administration in healthy male subjects. Presented at: 42nd Interscience Conference on Antimicrob Agents and Chemotherapy. San Diego, CA, USA, 27-30 September 2002 (Abstract).
59. Wexler D, Laughlin M, Courtney R et al.: Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur. J. Pharm. Sci. 21, 645 (2004).
60. Albengres E, Le Louet H, Tillement JP: Systemic antifungal agents: drug interactions of clinical significance. Drug Saf. 18, 83-97 (1998).
61. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ: Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet. 38, 111-180 (2000).
62. Courtney R, Martinho M, Lim J et al.: Evaluation of the effect of age, weights, race, and gender on posaconazole plasma concentrations in HIV-infected patients. Presented at: 3rd European Congress of Clinical Microbiology and Infectious Diseases. Glasgow. Scotland, UK, 10-13 May 2000 (Abstract).
63. Courtney R, Sansone A. Statkevich P et al.: Effect of age and gender on the pharmacokinetics of posaconazole in healthy volunteers. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 14-17 September 2003 (Abstract).
64. Courtney R, Sansone A, Kantesaria B et al.: Effect of ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA. 14-17 September 2003 (Abstract).
65. Courtney R. Laughlin M, Gontz H et al.: Single-dose pharmacokinetics of posaconazole in subjects with various degrees of chronic liver disease. Presented at: Annual Meeting of American Association of Pharmaceutical Scientists. Indianapolis, IN, USA 29 October - 2 November 2000 (Abstract).
66. Courtney R, Sansone A, Statkavich P et al.: Pharmacokinetics of posaconazole in subjects with varying degrees of renal insufficiency. Presented at: 13th European Congress of Clinical Microbiology and Infectious Diseases. Glasgow, Scotland, UK, 10-13 May 2003 (Abstract).
67. Vazquez JA, Skiest DJ, Nieto L et al.: A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin. Infect. Dis. 42, 1179-1186 (2006).
68. Skiest DJ, Vazquez JA, Anstead GM et al.: Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV-infection. Clin. Infect. Dis. 44, 607-614 (2007).
69. Vazquez JA, Skiest DJ, Tissot-Dupont H et al.: Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV Infection. HIV Clin. Trials (2007) (In Press).
70. Raad II, Hachem RY, Herbrecht R et al.: Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42, 1398 (2006).
71. van Burik JA, Hare RS, Solomon F et al.: Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42, E61 (2006).
72. Ullmann AJ, Lipton JH, Vesole DH et al.: Posaconazole vs fluconazole for prophylaxis of invasive fungal infections in allogenic hematopoietic stem cell transplant recipients with graft-versus-host disease. N. Engl. J. Med. 356, 335-347 (2007).
73. Pitisuttithum P. Gaona-Flores V. Negront R et al.: Efficacy of posaconazole in treatment of central nervous system fungal infections: results of an open-label study. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotheraphy. Chicago,, IL, USA 14-17 September 2003 (Abstract).